Answers are grounded in this paper and cite their sources.
lanzapine/samidorphan (OLZ/SAM) was released in October 2021 for adults with schizophrenia or bipolar I disorder in acute manic or mixed episodes and for maintenance to prevent manic and/ or depressive episodes. 1Samidorphan is a novel μ-opioid receptor antagonist and a κ-opioid and δ-opioid receptor partial agonist associated with regulation of appetite and metabolism. 2 Samidorphan has a longer half-life than naltrexone and 5 times the μ-opioid receptor blockade 3 that mitigates weight gain from olanzapine. 4 The following are representative cases drawn from a general pediatric and adult outpatient psychiatry practice located in Lower Hudson Valley, New York, demonstrating ancillary benefits we have consistently found.
No takes yet. Share an insight, caveat, or question.
Price et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: